Pradimicin A

Cat. No.: HY-132191: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Pradimicin A (PRM-A) is a potent antifungal agent, with an MIC of 4 μg/mL against Candida rugosa. Pradimicin A has antiviral activities against CoV, HIV and other enveloped viruses. Pradimicin A shows aggregation property, and can recognize d-Man in the presence of Ca²⁺ ion.

For research use only. We do not sell to patients.

Pradimicin A Chemical Structure

CAS No. : 117704-65-1

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

View All Isoforms

HIV HIV-1 HIV-2

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

MIC: 4 μg/mL (Candida rugosa)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
C8166	CC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against human C8166 cells after 3 to 4 days Cytotoxicity against human C8166 cells after 3 to 4 days	[PMID: 20047920]
C8166	EC₅₀	2.6 μM Compound: PRM-A	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
Caco-2	CC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against human Caco2 cells after 3 to 4 days Cytotoxicity against human Caco2 cells after 3 to 4 days	[PMID: 20047920]
CCRF-CEM	CC₅₀	> 100 μM Compound: PRM-A	Cytotoxicity against human CEM cells after 7 days by trypan blue staining Cytotoxicity against human CEM cells after 7 days by trypan blue staining	[PMID: 20047920]
CCRF-CEM	CC₅₀	> 100 μM Compound: Pradimicin A	Cytotoxicity against human CEM cells assessed as cell count after 3 days Cytotoxicity against human CEM cells assessed as cell count after 3 days	[PMID: 26513643]
CCRF-CEM	EC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against human CEM cells after 4 days by by Coulter counter analysis Cytotoxicity against human CEM cells after 4 days by by Coulter counter analysis	[PMID: 21749165]
CCRF-CEM	EC₅₀	> 50 μM Compound: PRM-A	Antiviral activity against HIV-1 3B harboring wild type gp120 infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-1 3B harboring wild type gp120 infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
CCRF-CEM	EC₅₀	3.3 μM Compound: Pradimicin A	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 26513643]
CCRF-CEM	EC₅₀	3.3 μM Compound: Pradimicin	Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	[PMID: 25617695]
CCRF-CEM	EC₅₀	3.4 μM Compound: PRM-A	Antiviral activity against HIV1 3B infected in human CD4+ T-lymphocyte CEM cells assessed as inhibition of virus-induced cytopathicity after 4 to 5 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CD4+ T-lymphocyte CEM cells assessed as inhibition of virus-induced cytopathicity after 4 to 5 days by microscopic analysis	[PMID: 26540494]
CCRF-CEM	EC₅₀	4.3 μM Compound: PRM-A	Antiviral activity against SIV mac251 infected in human HUT78 cells assessed as prevention of syncytium formation between persistently SIV mac251-infected HUT-78 cells and uninfected CEM cells after 3 to 4 days by ELISA Antiviral activity against SIV mac251 infected in human HUT78 cells assessed as prevention of syncytium formation between persistently SIV mac251-infected HUT-78 cells and uninfected CEM cells after 3 to 4 days by ELISA	[PMID: 20047920]
CCRF-CEM	EC₅₀	5.2 μM Compound: PRM-A	Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
CCRF-CEM	EC₅₀	5.2 μM Compound: PRM-A	Antiviral activity against compound pretreated HIV-1 3B isolate 42 harboring gp120 mutant infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against compound pretreated HIV-1 3B isolate 42 harboring gp120 mutant infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
CCRF-CEM	EC₅₀	5.2 μM Compound: PRM-A	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21749165]
CCRF-CEM	EC₅₀	5.9 μM Compound: PRM-A	Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
CCRF-CEM	EC₅₀	5.9 μM Compound: PRM-A	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21749165]
CCRF-CEM	EC₅₀	5.9 μM Compound: Pradimicin A	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 to 5 days by microscopic analysis	[PMID: 26513643]
CCRF-CEM	EC₅₀	5.9 μM Compound: Pradimicin	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay Antiviral activity against HIV2 ROD infected in human CEM cells assessed as reduction in virus-induced cytopathicity after 4 to 5 days by microscopy based syncytium cell formation assay	[PMID: 25617695]
HeLa	CC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against human HeLa cells after 3 to 4 days Cytotoxicity against human HeLa cells after 3 to 4 days	[PMID: 20047920]
L1210	CC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against mouse L1210 cells after 3 to 4 days Cytotoxicity against mouse L1210 cells after 3 to 4 days	[PMID: 20047920]
MOLT-4	CC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against human Molt4 cells after 3 to 4 days Cytotoxicity against human Molt4 cells after 3 to 4 days	[PMID: 20047920]
MT4	CC₅₀	> 100 μM Compound: PRM-A	Cytotoxicity against human MT4 cells assessed as cell viability measured after 5 days by MTS assay Cytotoxicity against human MT4 cells assessed as cell viability measured after 5 days by MTS assay	[PMID: 35512567]
MT4	CC₅₀	> 100 μM Compound: PRM-A	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay	[PMID: 34229438]
MT4	CC₅₀	> 100 μM Compound: PRM-A	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTS/PES assay	[PMID: 31809045]
MT4	CC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against human MT4 cells after 7 days by trypan blue staining Cytotoxicity against human MT4 cells after 7 days by trypan blue staining	[PMID: 20047920]
MT4	EC₅₀	5 μM Compound: PRM-A	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining	[PMID: 20047920]
MT4	EC₅₀	5.2 μM Compound: PRM-A	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining	[PMID: 20047920]
MT4	EC₅₀	5.5 μM Compound: PRM-A	Antiviral activity against SIV mac251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining Antiviral activity against SIV mac251 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 7 days by trypan blue staining	[PMID: 20047920]
OST	CC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against human thymidine kinase-negative OST cells after 3 to 4 days Cytotoxicity against human thymidine kinase-negative OST cells after 3 to 4 days	[PMID: 20047920]
PBMC	CC₅₀	> 250 μM Compound: PRM-A	Cytotoxicity against human PBMC after 7 days by trypan blue staining Cytotoxicity against human PBMC after 7 days by trypan blue staining	[PMID: 20047920]
PBMC	EC₅₀	> 50 μM Compound: PRM-A	Antiviral activity against HIV-1 3B cells infected in human PBMC cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis Antiviral activity against HIV-1 3B cells infected in human PBMC cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by microscopic analysis	[PMID: 20047920]
PBMC	CC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against human PBMC cells after 3 to 4 days Cytotoxicity against human PBMC cells after 3 to 4 days	[PMID: 20047920]
Raji	IC₅₀	16 μM Compound: PRM-A	Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA	[PMID: 20047920]
Raji	IC₅₀	16 μM Compound: PRM-A	Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 60 mins by ELISA Antiviral activity against SIV mac251 infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 60 mins by ELISA	[PMID: 20047920]
Raji	IC₅₀	21 μM Compound: PRM-A	Antiviral activity against R5 tropic HIV-1 Bal infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA Antiviral activity against R5 tropic HIV-1 Bal infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA	[PMID: 20047920]
Raji	EC₅₀	3.4 μM Compound: PRM-A	Antiviral activity against compound pretreated X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 4 Antiviral activity against compound pretreated X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 4	[PMID: 20047920]
Raji	IC₅₀	3.5 μM Compound: PRM-A	Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as inhibition of virus capture by Raji cells after 60 mins by ELISA	[PMID: 20047920]
Raji	EC₅₀	5.4 μM Compound: PRM-A	Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 36 to 42 hrs by micro Antiviral activity against X4 tropic HIV-1 3B infected in human Raji cells expressing DC-SIGN gene assessed as prevention of syncytium formation between persistently HIV-1 3B-infected Raji cells and uninfected human C8166 cells after 36 to 42 hrs by micro	[PMID: 20047920]
SUP-T1	EC₅₀	3.4 μM Compound: PRM-A	Antiviral activity against HIV-1 3B infected in human HUT78 cells assessed as prevention of syncytium formation between persistently HIV-1 3B-infected HUT-78 cells and uninfected SupT1 cells after 3 to 4 days by ELISA Antiviral activity against HIV-1 3B infected in human HUT78 cells assessed as prevention of syncytium formation between persistently HIV-1 3B-infected HUT-78 cells and uninfected SupT1 cells after 3 to 4 days by ELISA	[PMID: 20047920]
U-87MG ATCC	CC₅₀	> 50 μM Compound: PRM-A	Cytotoxicity against human U87 cells after 3 to 4 days Cytotoxicity against human U87 cells after 3 to 4 days	[PMID: 20047920]

Molecular Weight

840.78

Formula

C₄₀H₄₄N₂O₁₈

CAS No.

117704-65-1

SMILES

OC1=C2C3=C(O)C(C(N[C@H](C)C(O)=O)=O)=C(C)C=C3[C@@H]([C@H](C2=CC4=C1C(C5=CC(OC)=CC(O)=C5C4=O)=O)O)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)C)NC)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Miyanishi W, et al. d-Mannose binding, aggregation property, and antifungal activity of amide derivatives of pradimicin A. Bioorg Med Chem. 2021 Dec 27;55:116590. [Content Brief]

[2]. Nakagawa Y, Doi T, Masuda Y, Takegoshi K, Igarashi Y, Ito Y. Mapping of the primary mannose binding site of pradimicin A. J Am Chem Soc. 2011 Nov 2;133(43):17485-93. [Content Brief]

Pradimicin A Related Classifications

Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pradimicin A117704-65-1FungalSARS-CoVHIVSARS coronavirusHuman immunodeficiency virusAntifungal activityCandida rugosaCoVHuman immunodeficiency virus (HIV)Aggregation propertyAntiviral activityInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Pradimicin A

Pradimicin A Related Antibodies

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All HIV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Pradimicin A Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report